Pelacarsen (TQJ230) Clinical Trials
2 recruitingDrug
Phase 32
Showing 1–2 of 2 trials
Recruiting
Phase 3
Pelacarsen Roll-over Extension Program
Atherosclerotic Cardiovascular Disease
Novartis Pharmaceuticals599 enrolled97 locationsNCT06875973
Recruiting
Phase 3
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Cardiovascular Disease and Lipoprotein(a)
Novartis Pharmaceuticals5,700 enrolled72 locationsNCT07517263